List view / Grid view



BMS Phase II study in non-alcoholic steatohepatitis a success 

24 April 2017 | By Niamh Marriott, Junior Editor

BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.

Send this to a friend